Impact of Multi-Component Interventions on High Risk COPD Population
NCT ID: NCT06456996
Last Updated: 2025-03-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
NA
7400 participants
INTERVENTIONAL
2024-06-17
2026-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Intervention: Within the intervention arm, we have constructed a population-based pay-for-performance mechanism to encourage medical practitioners to care for population health. For study participants in the intervention arm, we will ask them to finish an online COPD-SQ questionnaire with notification of his or her COPD high risk status. Those whose score exceeds 16 will be invited to do a face-to-face survey, simple physical examination, pulmonary function tests, and provide a multi-component intervention at baseline. For High-risk COPD population in the intervention arm, we provide community-based spirometry pulmonary function test (PFT) and education; If individuals whose post-bronchodilator FEV1/FVC\<0.7, they will be spirometry-defined COPD patients and will be encouraged to seek treatment and medication to the superior hospitals. Additionally, we provide (1) two digital health intervention programs to smokers and individuals with mental health issues; (2) CBT-based health education for study participants with abnormal BMI; (3) active recruitment into National Essential Public Health Program in China for those with abnormal blood pressure and blood glucose. Intensive follow-ups will be conducted at month 3 (telephone interview), month 6 (face-to-face with full steps of physical examination), and month 12.
Comparison: Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given.
Outcomes: The primary outcomes are COPD knowledge, COPD screening, and FEV1 measurement at month 12.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Impact of Multi-Component Interventions on High-Risk COPD Smokers
NCT06458205
Xishui Project for IDM of COPD and Comorbidities
NCT06456749
Primary Health Management for Chronic Obstructive Pulmonary Disease
NCT06573580
COPD: A Multi-center Supervised Tele-rehabilitation Study
NCT06085261
Digital Therapy in Self-management of COPD Patients
NCT06776601
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention arm
Within the intervention arm, all medical practitioners will be under a pay-for-population mechanism to incentivize them to care for the overall population health within their township. For High-risk COPD population in the intervention arm, we provide community-based spirometry pulmonary function test (PFT) and education; If individuals whose post-bronchodilator FEV1/FVC\<0.7, they will be spirometry-defined COPD patients and will be encouraged to seek treatment and medication to the superior hospitals. Additionally, we provide (1) two digital health intervention programs to smokers and individuals with mental health issues; (2) CBT-based health education for study participants with abnormal BMI; (3) active recruitment into National Essential Public Health Program in China for those with abnormal blood pressure and blood glucose. Intensive follow-ups will be conducted at month 3 (telephone interview), month 6 (face-to-face with full steps of physical examination), and month 12.
Multi-component intervention package
1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;
2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);
3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);
4. Health education to smokers for smoking cessation;
5. Health education to individuals with mental health issues;
6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;
7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;
8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;
9. Pay-for-population mechanism for medical practitioners.
Control Arm
Those who are assigned in the control arm, we will ask them to finish the same COPD-SQ online questionnaire with notification of his or her COPD high risk status and a face-to-face survey. No physical examinations, community-based pulmonary function tests will be given at baseline. However, at month 12, we will provide community-based pulmonary function tests and physical examinations besides face-to-face survey.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Multi-component intervention package
1. Community-based spirometry pulmonary function tests and result interpretations and health education for COPD;
2. A digital health intervention program, NicQuit, for smokers(very familiar with intelligent mobile phone);
3. A digital health intervention program, EmoEase, for individuals whose WEMWBS questionnaire score is lower than 45(very familiar with intelligent mobile phone);
4. Health education to smokers for smoking cessation;
5. Health education to individuals with mental health issues;
6. Encouragement to seek professional medication treatment in superior hospitals for spirometry-defined COPD patients;
7. To actively include individuals whose blood pressurei s higher than 140/90 mmHg or/and whose random blood glucose higher than 11.1 mmol/L into the National Essential Public Health Service in China;
8. A CBT-based health education to the BMI abnormal, i.e., BMI \> 24.0 or BMI \< 18.5;
9. Pay-for-population mechanism for medical practitioners.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* COPD-SQ score is 16 and above;
* Residents who have lived in one township over the past 3 months and plan to reside in the same township in the upcoming year;
* Finished the informed consent.
Exclusion Criteria
* Severe cognitive disorder or total loss of capability of daily living
35 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Peking Union Medical College
OTHER
China-Japan Friendship Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Simiao Chen
Professor
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Simiao Chen, Ph.D.
Role: PRINCIPAL_INVESTIGATOR
Peking Union Medical College
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
26 township hospitals in Xishui County
Zunyi, Guizhou, China
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CAMS&PUMC-IEC-2024-040
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.